Abstract

Omeprazole (Prilosec) in the Atypical Patient, Administration of

Author(s): Kane Dana Lynn

Issue: Jan/Feb 1997 - Hospice Care

Page(s): 13

Download in electronic PDF format for $75

Abstract

Omeprazole, a proton pump inhibitor indicated for peptic ulcer disease, reflux esophagitis and hypersecretory conditions, is known to be inactivated by gastric acidity. In this article, the author provides suggestions for administering omeprazole to a patient who cannot swallow the capsule whole or who has a nasogastric or gastrostomy tube or a jejunostomy tube.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 1997 Pg. 13	Omeprazole (Prilosec) in the Atypical Patient, Administration of Author(s): Kane Dana Lynn
May/Jun 2022 Pg. 214-217	Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes Author(s): Allen Loyd V Jr
May/Jun 2010 Pg. 250-256	Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Author(s): de Villiers Melgardt M, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne
Jul/Aug 2010 Pg. 276-282	Recommendations for Compounding Medications for Feeding Tube Administration Author(s): Klang Mark
Sep/Oct 2006 Pg. 383	Fluconazole 1-mg/mL Liquid for Nasogastric Tube Administration Author(s): Allen Loyd V Jr
Jul/Aug 2000 Pg. 304	Nasogastric Tube/Percutaneous Endoscopic Gastrostomy Tube Suspension Formula Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 206-207	Technology Spotlight: Tube Sealers Author(s): Jones Michael, Adams Susan
Mar/Apr 2008 Pg. 163-169	Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting Author(s): de Oliveira Ferreira Anderson, Holandino Carla
May/Jun 2009 Pg. 250-253	Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding Author(s): Garg Sanjay, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
Sep/Oct 2006 Pg. 389	Omeprazole 2-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 504-510	Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid Author(s): Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
Nov/Dec 2017 Pg. 500-512	To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid Author(s): Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
Jul/Aug 2003 Pg. 258-263	Patient Satisfaction with Pharmacist Intervention and Consultation in HRT Author(s): DiMaggio Jennifer Lyn, Reed-Kane Dana
Mar/Apr 1997 Pg. 84-86	Compounding for the Pediatric Patient Author(s): Allen Loyd V Jr
May/Jun 2009 Pg. 224-229	Compounded Medications in a Hospital Setting: Patient Counseling and Staff Education Author(s): McElhiney Linda F
Jul/Aug 2013 Pg. 270-280	Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski
Jul/Aug 2013 Pg. 339-343	Patient-centered Care as Value-added Service by Compounding Pharmacists Author(s): McPherson Timothy B, Fontane Patrick E, Day Jonathan R
Mar/Apr 2012 Pg. 164-166	Stability of Omeprazole in SyrSpend SF Alka (Reconstituted) Author(s): Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
Jan/Feb 2018 Pg. 30-39	Basics of Compounding: Providing Pharmacy Services to Bariatric Surgery Patients Author(s): McElhiney Linda F
Jan/Feb 2019 Pg. 58	Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid Author(s): Allen Loyd V Jr